Pyridoxal phosphate de-activation by pyrroline-5-carboxylic acid: increased risk of vitamin B-6 deficiency and seizures in hyperprolinemia type II
Farrant, R. Duncan, Walker, Valerie, Mills, Graham A., Mellor, John M. and Langley, G. John (2001) Pyridoxal phosphate de-activation by pyrroline-5-carboxylic acid: increased risk of vitamin B-6 deficiency and seizures in hyperprolinemia type II. Journal of Biological Chemistry, 276, (18), 15107-15116. (doi:10.1074/jbc.M010860200).
Full text not available from this repository.
We previously identified vitamin B-6 deficiency in a child presenting with seizures whose primary diagnosis was the inherited disorder hyperprolinemia type II. This is an unrecognized association, which was not explained by diet or medication. We hypothesized that pyridoxal phosphate (vitamin B-6 coenzyme) was de-activated by L-Δ1-pyrroline-5-carboxylic acid, the major intermediate that accumulates endogenously in hyperprolinemia type II. The proposed interaction has now been investigated in vitro with high resolution H-1 nuclear magnetic resonance spectroscopy and mass spectrometry at a pH of 7.4 and temperature of 310 K. Three novel adducts were identified. These were the result of a Claisen condensation (or Knoevenagel type of reaction) of the activated C-4 carbon of the pyrroline ring with the aldehyde carbon of pyridoxal phosphate. The structures of the adducts were confirmed by a combination of high performance liquid chromatography, nuclear magnetic resonance, and mass spectrometry. This interaction has not been reported before. From preliminary observations, pyrroline-5-carboxylic acid also condenses with other aromatic and aliphatic aldehydes and ketones, and this may be a previously unsuspected generic addition reaction. Pyrroline-5 carboxylic acid is thus found to be a unique endogenous vitamin antagonist. Vitamin B-6 de-activation may contribute to seizures in hyperprolinemia type II, which are so far unexplained, but they may be preventable with long term vitamin B-6 supplementation.
|Keywords:||5-carboxylate dehydrogenase, pyrroline 5-carboxylate, rat-liver, metabolism, identification, spectroscopy, purification, diffusion, plasma|
|Subjects:||R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
Q Science > QD Chemistry
R Medicine > RJ Pediatrics > RJ101 Child Health. Child health services
|Divisions:||University Structure - Pre August 2011 > School of Chemistry
University Structure - Pre August 2011 > School of Medicine > Human Genetics
|Date Deposited:||15 Feb 2006|
|Last Modified:||01 Jun 2011 06:13|
|Contributors:||Farrant, R. Duncan (Author)
Walker, Valerie (Author)
Mills, Graham A. (Author)
Mellor, John M. (Author)
Langley, G. John (Author)
|Date:||4 May 2001|
|Contact Email Address:||Duncan.Farrant@gsk.com|
|RDF:||RDF+N-Triples, RDF+N3, RDF+XML, Browse.|
Actions (login required)